Masoomeh Faghankhani is a DrPH student in the Department of Community and Behavioral Health at the Colorado School of Public Health, advised by Dr. Jenn Leiferman. She earned her MD from Tehran University of Medical Sciences and an MPH in Mental and Behavioral Health from Washington University in St. Louis, where she was inducted into the Delta Omega Honorary Society of Public Health.
Masoomeh has extensive experience in mental and behavioral health research in both clinical and community settings. Her work focuses on early psychosis among adolescents and youth, women's mental and behavioral health issues, substance use behaviors, and the intersection of biological and structural/social/political determinants of mental health and illness. She has contributed to several multidisciplinary projects, including investigating risk factors and interventions for adolescents and young adults at clinical high risk for psychosis, as well as exploring perinatal mental health issues such as depression, anxiety, and the impacts of trauma and stress on women's health outcomes.
Currently, Masoomeh works on research projects examining the biological, environmental, and social factors that influence the mental and behavioral health of vulnerable populations. She is committed to advancing mental health equity through innovative, community-driven, evidence-based, and transdisciplinary approaches that empower underserved communities, particularly women and youth.
Areas of Expertise
- Clinical High Risk of Psychosis (CHR-p) among Adolescents and Young Adults
- Perinatal Women's Mental and Behavioral Health
- Substance Use
- Artificial Intelligence-based mHealth Interventions
- System Thinking in Public Health
- Dissemination and Implementation Science
Education, Licensure & Certifications
- DrPH, Community and Behavioral Health, Colorado School of Public Health, 2024 (expected)
- MPH, Mental and Behavioral Health, Washington University in St. Louis, 2024
- MD, Medicine, Tehran University of Medical Sciences, 2011
Awards
- Dean’s Scholarship in Public Health Leadership, Brown School at Washington University in St. Louis, 2022
Affiliations
- Student Assistant V, Connections Program for High-Risk Infants and Families, Department of Psychiatry, University of Colorado - Anschutz Medical Campus
- Research Assistant, Washington Early Recognition Center, Department of Psychiatry, Washington University School of Medicine
Publications and Presentations
- Faghankhani M, Sodagari F, Shokrani M, Baradaran HR, Adabi A, Zabihi M, Adeli AM, Fathimakvand M, Golalipour E, Aghdasi S, Javanbakht A, Nadoushan AHJ. Perceived Stress among Iranians during COVID-19 Pandemic; Stressors and Coping Mechanisms: A Mixed-methods Approach. Can J Psychiatry. 2022 Dec;67(12):918-927. doi: 10.1177/07067437211004881. Epub 2021 Apr 1. PMID: 33792374; PMCID: PMC9659483
- Kashanian M, Faghankhani M, YousefzadehRoshan M, EhsaniPour M, Sheikhansari N. Woman's perceived stress during pregnancy; stressors and pregnancy adverse outcomes. J Matern Fetal Neonatal Med. 2021 Jan;34(2):207-215. doi: 10.1080/14767058.2019.1602600. Epub 2019 Apr 8. PMID: 30931659
- Mamah D, Mutiso V, Musyimi C, Harms MP, Anokhin AP, Chen S, Torous J, Muyela L, Nashed J, Al-Hosni Y, Odera A, Yarber A, Golosheykin S, Faghankhani M, Sneed M, Ndetei DM. Kenya Psychosis-Risk Outcomes Study (KePROS): Development of an Accelerated Medicine Partnership Schizophrenia-Aligned Project in Africa. Schizophr Bull Open. 2024 May 4;5(1):sgae009. doi: 10.1093/schizbullopen/sgae009. PMID: 39144113; PMCID: PMC11207935
- Faghankhani M, Nourinia H, Rafiei-Rad AA, Adeli AM, Yeganeh MRJ, Sharifi H, Namazi H, Khosravifar S, Bahramian A, Fathimakvand M, Golalipour E, Mirfazeli FS, Baradaran HR, Thornicroft G, Jalali Nadoushan AH. COVID-19 related stigma among the general population in Iran. BMC Public Health. 2022 Sep 5;22(1):1681. doi: 10.1186/s12889-022-14039-2. PMID: 36064385; PMCID: PMC9442561
- Abdolmaleky HM, Pajouhanfar S, Faghankhani M, Joghataei MT, Mostafavi A, Thiagalingam S. Antipsychotic drugs attenuate aberrant DNA methylation of DTNBP1 (dysbindin) promoter in saliva and post-mortem brain of patients with schizophrenia and Psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2015 Dec;168(8):687-96. doi: 10.1002/ajmg.b.32361. Epub 2015 Aug 18. PMID: 26285059